Skip to main content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Molecular mechanisms of azole resistance in Candida bloodstream isolates

BMC Infectious Diseases201919:63

https://doi.org/10.1186/s12879-019-3672-5

  • Received: 5 March 2018
  • Accepted: 2 January 2019
  • Published:
Open Peer Review reports

Abstract

Background

Antifungal resistance rates are increasing. We investigated the mechanisms of azole resistance of Candida spp. bloodstream isolates obtained from a surveillance study conducted between 2012 and 2015.

Methods

Twenty-six azole non-susceptible Candida spp. clinical isolates were investigated. Antifungal susceptibilities were determined using the Sensititre YeastOne® YO10 panel. The ERG11 gene was amplified and sequenced to identify amino acid polymorphisms, while real-time PCR was utilised to investigate the expression levels of ERG11, CDR1, CDR2 and MDR1.

Results

Azole cross-resistance was detected in all except two isolates. Amino acid substitutions (A114S, Y257H, E266D, and V488I) were observed in all four C. albicans tested. Of the 17 C. tropicalis isolates, eight (47%) had ERG11 substitutions, of which concurrent observation of Y132F and S154F was the most common. A novel substitution (I166S) was detected in two of the five C. glabrata isolates. Expression levels of the various genes differed between the species but CDR1 and CDR2 overexpression appeared to be more prominent in C. glabrata.

Conclusions

There was interplay of various different mechanisms, including mechanisms which were not studied here, responsible for azole resistance in Candida spp in our study.

Keywords

  • Candida
  • Antifungal resistance
  • Genomics

Background

Candida bloodstream infections are an important healthcare issue known to be associated with high morbidity and mortality. There have been increasing reports of antifungal resistance. We have previously reported decreasing azole susceptibilities in our hospital, particular in Candida tropicalis. More than 20% of C. tropicalis were non-susceptible to fluconazole [1]. There are various mechanisms mediating azole resistance. It has been suggested that molecular mechanisms such as presence of mutations may be a predictive marker of clinical failure in Candida infections [2]. Whilst this has been established for echinocandin resistance, azole resistance mechanisms are not as well studied, particularly for non-albicans species. Elucidation of these mechanisms is crucial to make progress in understanding and treating invasive Candida infections.

Methods

In this study, we characterised the molecular mechanisms of azole resistance in 26 fluconazole non-susceptible Candida bloodstream isolates. These isolates were identified from a retrospective surveillance study conducted at a major regional tertiary referral hospital between 2012 and 2015 [1]. In brief, non-duplicate Candida bloodstream isolates from all adult inpatients (at least 21 years old) with temporally-related clinical signs and symptoms of infection admitted to the hospital during the study period were included. Antifungal susceptibility testing was performed using Sensititre YeastOne® YO10 panel (Trek Diagnostics System, West Sussex, England) according to manufacturer’s recommendations. Minimum inhibitory concentrations were interpreted according to the current species-specific clinical breakpoints provided by the Clinical and Laboratory Standards Institute (CLSI) M27-S4 document or epidemiological cut-off values (ECV), where CLSI breakpoints were unavailable [3, 4]. For Candida albicans and C. tropicalis, isolates meeting the susceptible-dose-dependent (SDD) and resistant criteria were included, whereas only resistant Candida glabrata were included in this study. A total of 26 fluconazole non-susceptible isolates [C. albicans - 4/62 (6%); C. glabrata - 5/82 (6%); C. tropicalis - 17/78 (22%); C. parapsilosis - 0/35 (0%)] were identified from 257 Candida spp. isolates included in the surveillance study.

ERG11, CDR1, CDR2 and MDR1 gene expression were quantified in triplicates using real-time reverse transcription-PCR (RTPCR) with total RNA extracted from exponential-phase yeast peptone dextrose broth cultures on a CFX96 Real-Time PCR Detection System (Bio-Rad, USA). The primers used were adopted from previous publications [511], except for C. glabrata CDR1 gene [F – TGGTGTTGCTAATGTCGCCA, R – GTCCCAAGTACTCGCCACAA] and C. glabrata ERG11 gene [F – CCACCCATTGCACTCTTTGT, R – AGAACGTGGTAGTCCCTTGG]. Quantification of target genes was normalised to the level of ACT1, an endogenous reference gene. Relative gene expression was calculated as the fold change in expression of the isolates compared to the respective ATCC reference strains (C. albicans ATCC 90028, C. glabrata ATCC 2950, C. tropicalis ATCC 750). A fold increase of 3 times was considered to be an overexpression of the target gene. The ERG11 gene was amplified and sequenced to identify amino acid mutations by comparing with reference wild-type GenBank sequences (C. albicans – X13296; C. tropicalis – M23673; C. glabrata – L40389).

Results

The susceptibility profiles of the isolates are displayed in Table 1. Cross-resistance to all azoles was observed in all isolates except for one C. albicans (CW138) and two C. glabrata (CW262 and CW378) isolates. All isolates retained susceptibility to other anti-fungals including anidulafungin, caspofungin, micafungin and amphotericin B (data not shown). In C. albicans, all isolates showed non-synonymous homozygous ERG11 substitutions which included three distinct substitutions (A114S, Y257H and E266D). I166S substitutions were detected in two of the six C. glabrata isolates. Of the 17 C. tropicalis isolates, eight (47%) had ERG11 substitutions. The most common substitutions were the concurrent observation of Y132F and S154F, which occurred primarily in resistant isolates with fluconazole MICs ≥8 μg/mL. Only two of the eight ERG11 substitutions were homozygous, and there does not appear to be any correlation of the type of substitutions with MICs. The ERG11 substitutions observed in all of the Candida spp. have been previously reported in literature except for I166S.
Table 1

Molecular characteristics of clinical fluconazole non-susceptible Candida spp. blood isolates

Isolate reference

MIC, ug/mL

Gene expression (fold increase)

Erg11p amino acid substitution(s)

FLC

VRC

POS

ERG11

CDR1

CDR2

MDR1

 

C. albicans

CW138

4 (SDD)

0.12 (S)

0.25 (NWT)

0.41

1.60

9.01

0.18

A114S, Y257H

CW357

4 (SDD)

0.25 (SDD)

0.25 (NWT)

0.18

1.08

5.79

0.15

A114S, Y257H

CW241

128 (R)

4 (R)

1 (NWT)

0.58

4.49

122.50

141.28

A114S, Y257H

CW216

128 (R)

≥8 (R)

≥8 (NWT)

0.15

0.79

3.32

4.86

E266D, V488I

C. glabrata

CW193

64 (R)

4 (NWT)

≥8 (NWT)

0.46

23.12

23.24

N.A.

None

CW262

64 (R)

0.25 (WT)

0.5 (WT)

1.08

22.45

7.13

N.A.

I166S

CW378

64 (R)

4 (NWT)

2 (WT)

0.56

4.02

8.08

N.A.

None

CW088

≥256 (R)

4 (NWT)

≥8 (NWT)

1.10

19.78

14.55

N.A.

None

CW404

≥256 (R)

≥8 (NWT)

≥8 (NWT)

0.29

18.70

6.92

N.A.

I166S

C. tropicalis

CW190

4 (SDD)

0.25 (SDD)

0.5 (NWT)

0.39

6.11

N.A.

0.47

None

CW219

4 (SDD)

0.5 (R)

0.5 (NWT)

0.95

1.56

N.A.

0.77

None

CW361

4 (SDD)

0.5 (R)

0.25 (NWT)

2.38

0.27

N.A.

0.01

None

CW395

4 (SDD)

0.5 (R)

0.5 (NWT)

0.45

0.63

N.A.

3.27

None

CW071

8 (R)

0.25 (SDD)

0.5 (NWT)

0.11

1.28

N.A.

30.53

None

CW018

16 (R)

0.25 (SDD)

0.25 (NWT)

0.61

2.75

N.A.

23.42

Y132F, S154F

CW107

16 (R)

1 (R)

0.5 (NWT)

0.36

0.09

N.A.

7.12

Y132F, S154F

CW178

16 (R)

0.5 (R)

1 (NWT)

2.83

3.81

N.A.

0.64

None

CW385

16 (R)

0.5 (R)

1 (NWT)

0.12

4.43

N.A.

2.93

None

CW263

64 (R)

4 (R)

0.12 (NWT)

4.45

1.95

N.A.

1.44

Y132F, S154F

CW386

128 (R)

2 (R)

4 (NWT)

1.36

0.68

N.A.

1.33

None

CW065

≥256 (R)

4 (R)

0.5 (NWT)

1.04

1.30

N.A.

23.07

Y132F, S154F

CW067

≥256 (R)

≥8 (R)

1 (NWT)

0.11

0.93

N.A.

7.04

Y132F, S154F, F145 L

CW192

≥256 (R)

≥8 (R)

1 (NWT)

1.36

0.76

N.A.

0.52

Y132F, S154F

CW242

≥256 (R)

≥8 (R)

1 (NWT)

0.50

6.10

N.A.

1.21

Y132F, S154F

CW266

≥256 (R)

4 (R)

0.25 (NWT)

0.27

10.08

N.A.

1.59

None

CW271

≥256 (R)

≥8 (R)

1 (NWT)

7.47

1.30

N.A.

0.31

Y132F, S154F

FLC Fluconazole, VRC Voriconazole, POS Posaconazole, S Susceptible, SDD Susceptible dose-dependent, R Resistant, WT Wild-type, NWT Non wild-type, values in bold represent gene overexpression; underlined values represent heterozygous substitutions

Among the different gene targets, it appeared that ERG11 expression levels were mostly similar compared to the respective wild-type reference strains. CDR2 expression was consistently elevated in fluconazole non-susceptible C. albicans. In the two resistant isolates with MIC 128 μg/mL, MDR1 was also up-regulated. CDR1 and CDR2 co-expression was observed in all C. glabrata isolates. Gene overexpression was not consistent among C. tropicalis isolates – there were five isolates with CDR1 overexpression and six isolates with MDR1 overexpression. All C. tropicalis isolates only had overexpression of a single gene target. Interestingly, there were three C. tropicalis isolates with no ERG11 mutations or any gene up-regulation.

Discussion

In this study, we evaluated the molecular mechanisms associated with azole resistance in various Candida species in our institution. Identification of antifungal susceptibilities through phenotypic methods such as MIC testing is often limited by the length of time required. Furthermore, current fungal MIC breakpoint interpretations are not supported by robust clinical data and are not predictive of clinical success/failure. Therefore, there is interest in identifying genotypic markers which could be rapidly identified for use in clinical prediction. Various previous studies have investigated different mechanisms of azole resistance in Candida species [5, 1214]. Some of these studies have identified key ERG11 substitutions which are associated with azole resistance e.g. Y132F, S154F [8, 15] and suggested that these mutations could be potential predictive markers of azole resistance.

In our context, it appeared that there was an interplay of various different mechanisms, including mechanisms which were not studied here, responsible for azole resistance in Candida spp. ERG11 mutations were commonly detected in C. albicans, whereas the role of overexpression of azoles efflux pumps appeared to be more prominent in C. albicans (CDR1) and C. glabrata (CDR1, CDR2). In C. tropicalis, presence of Y132F and S154F substitutions was unable to explain the mechanisms of majority of our isolates. Less than half of the azole-resistant C. tropicalis harboured these amino acid substitutions. This was in contrast to the high frequency identified in another local study where > 90% of the isolates had Y132F and S154F substitutions [15]. Likewise, in another study, these mutations accounted for 95% of the fluconazole-resistant C. tropicalis [16].

Our study was limited by the small sample size although we had included all azole-resistant bloodstream isolates between 2012 and 2015. In addition, we did not perform further functional verification of the ERG11 mutations and homology modelling experiments, therefore the clinical significance of I166S amino acid substitution in C. glabrata remains to be validated.

Conclusions

In conclusion, our results indicated that the mechanisms mediating azole resistance in our isolates are heterogeneous. There were isolates with unidentified resistance mechanisms warranting further exploration. Moving ahead, the use of more advanced molecular technologies such as next-generation sequencing might be considered for an in-depth molecular characterisation of azole-resistant Candida spp to aid the identification of potential resistance markers.

Abbreviations

ATCC: 

American Type Culture Collection

CLSI: 

Clinical and Laboratory Standards Institute

ECV: 

Epidemiological cut-off values

PCR: 

Polymerase chain reaction

RTPCR: 

Real-time reverse-transcription polymerase chain reaction

Declarations

Acknowledgements

The authors acknowledge the excellent assistance of lab members of the Microbiology Lab, in particular Ms. Tan Mei Gie, and staff of the Pharmacy Research Lab, Singapore General Hospital, in the collection of the isolates. This study was presented in part at the 27th European Congress of Clinical Microbiology & Infectious Diseases, Vienna, Austria, 22nd – 25th April 2017 and the ASM Microbe 2017 meeting, New Orleans, USA, 1st – 5th June 2017.

Funding

This study was funded by grants from National Medical Research Council (NMRC/TA/0025/2013 and NMRC/CG/016/2013); and Pfizer Inc. (WS2347894). The study was also supported in part by Astellas Pharma Singapore Pte Ltd. with materials donation. The funders had no involvement in the study design, in the collection, analysis and interpretation of the data, or in the decision to submit the article for publication.

Availability of data and materials

Please contact corresponding author for data requests.

Authors’ contributions

JQT, SJL, RSL, YC, TPL and ALT participated in the microbiological and/or molecular experiments. JQT and ALK conceived the study, interpreted the results, revised the manuscript and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The research protocol was approved by the Singhealth Centralised Institutional Review Board (2013/987/D). Informed consent was waived in view of retrospective nature of study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pharmacy, Singapore General Hospital, Blk 8 Level 2, Outram Road, Singapore, 169608, Singapore
(2)
Saw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive 2, #10-01, Singapore, 117549, Singapore
(3)
Department of Microbiology, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore
(4)
Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore
(5)
Singhealth Duke-NUS Pathology Academic Clinical Programme, 8 College Road, Level 4, Singapore, 169857, Singapore
(6)
Singhealth Duke-NUS Medicine Academic Clinical Programme, 8 College Road, Level 4, Singapore, 169857, Singapore
(7)
Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 8 College Rd, Singapore, 169857, Singapore
(8)
Present address: Program in Health Services and Systems Research, Duke-National University of Singapore Medical School, 8 College Rd, Singapore, 169857, Singapore

References

  1. Teo JQ, Candra SR, Lee SJ, Chia SY, Leck H, Tan AL, Neo HP, Leow KW, Cai Y, Ee RP, et al. Candidemia in a major regional tertiary referral hospital - epidemiology, practice patterns and outcomes. Antimicrob Resist Infect Control. 2017;6:27.View ArticleGoogle Scholar
  2. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56(9):4862–9.View ArticleGoogle Scholar
  3. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. CLSI document M27-S4. Wayne: Clinical and Laboratory Standards Institute; 2012.Google Scholar
  4. Canton E, Peman J, Iniguez C, Hervas D, Lopez-Hontangas JL, Pina-Vaz C, Camarena JJ, Campos-Herrero I, Garcia-Garcia I, Garcia-Tapia AM, et al. Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol. 2013;51(8):2691–5.View ArticleGoogle Scholar
  5. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother. 2005;49(11):4608–15.View ArticleGoogle Scholar
  6. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004;48(6):2124–31.View ArticleGoogle Scholar
  7. Mane A, Vidhate P, Kusro C, Waman V, Saxena V, Kulkarni-Kale U, Risbud A. Molecular mechanisms associated with fluconazole resistance in clinical Candida albicans isolates from India. Mycoses. 2016;59(2):93–100.View ArticleGoogle Scholar
  8. Jiang C, Dong D, Yu B, Cai G, Wang X, Ji Y, Peng Y. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother. 2013;68(4):778–85.View ArticleGoogle Scholar
  9. Caudle KE, Barker KS, Wiederhold NP, Xu L, Homayouni R, Rogers PD. Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot Cell. 2011;10(3):373–83.View ArticleGoogle Scholar
  10. Li QQ, Skinner J, Bennett JE. Evaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment. BMC Mol Biol. 2012;13:22.View ArticleGoogle Scholar
  11. Chen LM, Xu YH, Zhou CL, Zhao J, Li CY, Wang R. Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations. J Int Med Res. 2010;38(2):536–45.View ArticleGoogle Scholar
  12. Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother. 2000;44(10):2693–700.View ArticleGoogle Scholar
  13. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49(2):668–79.View ArticleGoogle Scholar
  14. Eddouzi J, Parker JE, Vale-Silva LA, Coste A, Ischer F, Kelly S, Manai M, Sanglard D. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob Agents Chemother. 2013;57(7):3182–93.View ArticleGoogle Scholar
  15. Chew KL, Cheng JWS, Jureen R, Lin RTP, Teo JWP. ERG11 mutations are associated with high-level azole resistance in clinical Candida tropicalis isolates, a Singapore study. Mycoscience. 2017;58(2):111–5.View ArticleGoogle Scholar
  16. Fan X, Xiao M, Zhang D, Huang JJ, Wang H, Hou X, Zhang L, Kong F, Chen SC, Tong ZH, et al. Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China. Clin Microbiol Infect. 2018. https://doi.org/10.1016/j.cmi.2018.11.007. Epub ahead of print.

Copyright

© The Author(s). 2019

Advertisement